UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) In a release issued under the same headline earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note that in the
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021), a clinical-stage biotechnology company focused on developing bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer